Variations in plasma and urinary lipids in response to enzyme replacement therapy for Fabry disease patients by nanoflow UPLC-ESI-MS/MS

Seul Kee Byeon, Jin Yong Kim, Jin Sung Lee, Myeong Hee Moon

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

A deficiency of α-galactosidase A causes Fabry disease (FD) by disrupting lipid metabolism, especially trihexosylceramide (THC). Enzyme replacement therapy (ERT) is clinically offered to FD patients in an attempt to lower the accumulated lipids. Studies on specific types of lipids that are directly or indirectly altered by FD are very scarce, even though they are crucial in understanding the biological process linked to the pathogenesis of FD. We performed a comprehensive lipid profiling of plasma and urinary lipids from FD patients with nanoflow liquid chromatography electrospray-ionization tandem mass spectrometry (nLC-ESI-MS/MS) and identified 129 plasma and 111 urinary lipids. Among these, lipids that exhibited alternations (>twofold) in patients were selected as targets for selected reaction monitoring (SRM)-based high-speed quantitation using nanoflow ultra-performance LC-ESI-MS/MS (nUPLC-ESI-MS/MS) and 31 plasma and 26 urinary lipids showed significant elevation among FD patients. Higher percentages of sphingolipids (SLs; 48 % for plasma and 42 % for urine) were highly elevated in patients; whereas, a smaller percentage of phospholipids (PLs; 15 % for plasma and 13 % for urine) were significantly affected. Even though α-galactosidase A is reported to affect THC only, the results show that other classes of lipids (especially SLs) are changed as well, indicating that FD not only alters metabolism of THC but various classes of lipids too. Most lipids showing significant increases in relative amounts before ERT decreased after ERT, but overall, ERT influenced plasma lipids more than urinary lipids. [Figure not available: see fulltext].

Original languageEnglish
Pages (from-to)2265-2274
Number of pages10
JournalAnalytical and Bioanalytical Chemistry
Volume408
Issue number9
DOIs
Publication statusPublished - 2016 Mar 1

Fingerprint

Enzyme Replacement Therapy
Fabry Disease
Lipids
Plasmas
Enzymes
Trihexosylceramides
Galactosidases
Urine
Biological Phenomena
Electrospray ionization
Sphingolipids
Electrospray Ionization Mass Spectrometry
Liquid chromatography
Tandem Mass Spectrometry
Lipid Metabolism
Metabolism
Liquid Chromatography
Mass spectrometry
Phospholipids

All Science Journal Classification (ASJC) codes

  • Analytical Chemistry
  • Biochemistry

Cite this

@article{a5ee698de184496fb6402cdaf7245f43,
title = "Variations in plasma and urinary lipids in response to enzyme replacement therapy for Fabry disease patients by nanoflow UPLC-ESI-MS/MS",
abstract = "A deficiency of α-galactosidase A causes Fabry disease (FD) by disrupting lipid metabolism, especially trihexosylceramide (THC). Enzyme replacement therapy (ERT) is clinically offered to FD patients in an attempt to lower the accumulated lipids. Studies on specific types of lipids that are directly or indirectly altered by FD are very scarce, even though they are crucial in understanding the biological process linked to the pathogenesis of FD. We performed a comprehensive lipid profiling of plasma and urinary lipids from FD patients with nanoflow liquid chromatography electrospray-ionization tandem mass spectrometry (nLC-ESI-MS/MS) and identified 129 plasma and 111 urinary lipids. Among these, lipids that exhibited alternations (>twofold) in patients were selected as targets for selected reaction monitoring (SRM)-based high-speed quantitation using nanoflow ultra-performance LC-ESI-MS/MS (nUPLC-ESI-MS/MS) and 31 plasma and 26 urinary lipids showed significant elevation among FD patients. Higher percentages of sphingolipids (SLs; 48 {\%} for plasma and 42 {\%} for urine) were highly elevated in patients; whereas, a smaller percentage of phospholipids (PLs; 15 {\%} for plasma and 13 {\%} for urine) were significantly affected. Even though α-galactosidase A is reported to affect THC only, the results show that other classes of lipids (especially SLs) are changed as well, indicating that FD not only alters metabolism of THC but various classes of lipids too. Most lipids showing significant increases in relative amounts before ERT decreased after ERT, but overall, ERT influenced plasma lipids more than urinary lipids. [Figure not available: see fulltext].",
author = "Byeon, {Seul Kee} and Kim, {Jin Yong} and Lee, {Jin Sung} and Moon, {Myeong Hee}",
year = "2016",
month = "3",
day = "1",
doi = "10.1007/s00216-016-9318-1",
language = "English",
volume = "408",
pages = "2265--2274",
journal = "Fresenius Zeitschrift fur Analytische Chemie",
issn = "0016-1152",
publisher = "Springer Verlag",
number = "9",

}

Variations in plasma and urinary lipids in response to enzyme replacement therapy for Fabry disease patients by nanoflow UPLC-ESI-MS/MS. / Byeon, Seul Kee; Kim, Jin Yong; Lee, Jin Sung; Moon, Myeong Hee.

In: Analytical and Bioanalytical Chemistry, Vol. 408, No. 9, 01.03.2016, p. 2265-2274.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Variations in plasma and urinary lipids in response to enzyme replacement therapy for Fabry disease patients by nanoflow UPLC-ESI-MS/MS

AU - Byeon, Seul Kee

AU - Kim, Jin Yong

AU - Lee, Jin Sung

AU - Moon, Myeong Hee

PY - 2016/3/1

Y1 - 2016/3/1

N2 - A deficiency of α-galactosidase A causes Fabry disease (FD) by disrupting lipid metabolism, especially trihexosylceramide (THC). Enzyme replacement therapy (ERT) is clinically offered to FD patients in an attempt to lower the accumulated lipids. Studies on specific types of lipids that are directly or indirectly altered by FD are very scarce, even though they are crucial in understanding the biological process linked to the pathogenesis of FD. We performed a comprehensive lipid profiling of plasma and urinary lipids from FD patients with nanoflow liquid chromatography electrospray-ionization tandem mass spectrometry (nLC-ESI-MS/MS) and identified 129 plasma and 111 urinary lipids. Among these, lipids that exhibited alternations (>twofold) in patients were selected as targets for selected reaction monitoring (SRM)-based high-speed quantitation using nanoflow ultra-performance LC-ESI-MS/MS (nUPLC-ESI-MS/MS) and 31 plasma and 26 urinary lipids showed significant elevation among FD patients. Higher percentages of sphingolipids (SLs; 48 % for plasma and 42 % for urine) were highly elevated in patients; whereas, a smaller percentage of phospholipids (PLs; 15 % for plasma and 13 % for urine) were significantly affected. Even though α-galactosidase A is reported to affect THC only, the results show that other classes of lipids (especially SLs) are changed as well, indicating that FD not only alters metabolism of THC but various classes of lipids too. Most lipids showing significant increases in relative amounts before ERT decreased after ERT, but overall, ERT influenced plasma lipids more than urinary lipids. [Figure not available: see fulltext].

AB - A deficiency of α-galactosidase A causes Fabry disease (FD) by disrupting lipid metabolism, especially trihexosylceramide (THC). Enzyme replacement therapy (ERT) is clinically offered to FD patients in an attempt to lower the accumulated lipids. Studies on specific types of lipids that are directly or indirectly altered by FD are very scarce, even though they are crucial in understanding the biological process linked to the pathogenesis of FD. We performed a comprehensive lipid profiling of plasma and urinary lipids from FD patients with nanoflow liquid chromatography electrospray-ionization tandem mass spectrometry (nLC-ESI-MS/MS) and identified 129 plasma and 111 urinary lipids. Among these, lipids that exhibited alternations (>twofold) in patients were selected as targets for selected reaction monitoring (SRM)-based high-speed quantitation using nanoflow ultra-performance LC-ESI-MS/MS (nUPLC-ESI-MS/MS) and 31 plasma and 26 urinary lipids showed significant elevation among FD patients. Higher percentages of sphingolipids (SLs; 48 % for plasma and 42 % for urine) were highly elevated in patients; whereas, a smaller percentage of phospholipids (PLs; 15 % for plasma and 13 % for urine) were significantly affected. Even though α-galactosidase A is reported to affect THC only, the results show that other classes of lipids (especially SLs) are changed as well, indicating that FD not only alters metabolism of THC but various classes of lipids too. Most lipids showing significant increases in relative amounts before ERT decreased after ERT, but overall, ERT influenced plasma lipids more than urinary lipids. [Figure not available: see fulltext].

UR - http://www.scopus.com/inward/record.url?scp=84957990742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957990742&partnerID=8YFLogxK

U2 - 10.1007/s00216-016-9318-1

DO - 10.1007/s00216-016-9318-1

M3 - Article

C2 - 26873218

AN - SCOPUS:84957990742

VL - 408

SP - 2265

EP - 2274

JO - Fresenius Zeitschrift fur Analytische Chemie

JF - Fresenius Zeitschrift fur Analytische Chemie

SN - 0016-1152

IS - 9

ER -